Chagas disease (CD) is a tropical neglected illness, affecting mainly populations of low socioeconomic status in Latin America. An estimated 6 to 8 million people worldwide are infected with Trypanosoma cruzi, the etiological agent of CD. Despite being one of the main global health problems, this disease continues without effective treatment during the chronic phase of the infection. The limitation of therapeutic strategies has been one of the biggest challenges on the fight against CD. Nifurtimox and benznidazole, developed in the 1970s, are still the only commercial options with established efficacy on CD. However, the efficacy of these drugs have a proven efficacy only during early infection and the benefits in the chronic phase are questionable. Consequently, there is a growing need for new pharmacological alternatives, either by optimization of existing drugs or by the formulation of new compounds. In the present study, a literature review of the currently adopted therapy, its concomitant combination with other drugs, and potential future treatments for CD was performed, considering articles published from 2012. The revised articles were selected according to the protocol of treatment: evaluation of drug association, drug repositioning and research of new drugs. As a result of the present revision, it was possible to conclude that the use of benznidazole in combination with other compounds showed better results when compared with its use as a single therapy. The search of new drugs has been the strategy most used in pursuing more effective forms of treatment for CD. However, studies have still focused on basic research, that is, they are still in a pre-clinical stage, using methodologies based on in vitro or in animal studies.
Chagas disease (CD) is an endemic anthropozoonosis caused by the hemoflagellate protozoan Trypanosoma cruzi and transmitted mainly by hematophagous triatomines. CD is the most common fatal infection in Central and South America affecting, in endemic countries, about eight million people and causing the death of approximately 50,000 individuals each year (WHO, 2018) . T. cruzi acute infection is usually asymptomatic and tissue damage may be detected decades after the first contact (Pérez- Molina and Molina, 2018) . The main clinical alteration during the chronic stage are electrocardiographic abnormalities followed by contraction alterations that can lead to heart failure and, in many cases, to sudden death (Bocchi, 2017) . CD cardiopathy results in progressive inability to continue working with a consequent overload of the country health system (Da Nóbrega et al., 2014) .
No satisfactory treatment exists for CD, especially for the chronic stage of the disease (Morillo et al., 2015) . The high costs associated with research and development of new drugs, coupled with the usually low financial return, results in the absence of new medicines. There is, consequently, an urgent need for novel alternatives and effective treatments for this disease. Several lines of research are presently being developed aiming to this objective, either trying to improve existing therapy or focusing in the development of new drugs. These topics will be reviewed in the present work that also intends to highlight the current perspectives on new approaches to the therapy of CD.
Available medicines for Chagas disease
After the first description of the disease, several compounds were tried as therapeutic agents (Fig. 1) , such as arsenic, fuchsin, emetic tartrate and mercury chloride (Coura and Castro, 2002; Dias et al., 2009 ). However, all failed to produce satisfactory results. The antiseptic gentian violet was also used in the past, but it is currently used ex-treatment of CD. Among them, the antimicrobial nitrofurans, of which the nitrofurfurylidene, known as nifurtimox ((RS)-3-methyl-N-[(1E)-(5nitro-2-furyl)methylene] thiomorpholin-4-amine 1,1-dioxide) (NF) and produced by the Bayer company under the trade name Lampit®, showed an improved effectiveness. The mechanism of action of this drug is not completely elucidated. Initially, NF was believed to act by oxidative stress, generating free radicals (Sales Junior et al., 2017) . However, some studies have showed that its activity depends on a type 1 trypanosomal nitroreductase (NTR), refuting the oxidative stress as the determining factor (Hall et al., 2011; Boiani et al., 2010) .
Because of its high toxicity, NF was progressively discontinued and its commercialization was suspended in Brazil, Argentina, Chile and Uruguay (Coura and Castro, 2002) from the 1980's. However, in these countries NF is retained as an option when treatment with BNZ fails, requiring authorization from PAHO or WHO for its use (Dias et al., 2016) . Of note, resistance to nitroheterocyclic compounds have been reported (Mejia et al., 2012; Wilkinson et al., 2009) , which seems to be associated with the loss of a single copy of the TcNTR gene (Wilkinson et al., 2008) . Trying to solve toxicity and resistance limitations, clinical studies have been conducted to change the dose of NF tablet without losing effectiveness reviewed by Sales Junior et al., 2017. Currently, the only drug available in most Latin American countries is benznidazole (BNZ). Initially produced by the pharmaceutical company Roche (Rochagan® and Radanil®), BNZ is now exclusively manufactured by the Pharmaceutical Laboratory of the State of Pernambuco (Lafepe), Brazil, and by the private laboratory Elea (Abarax®), Argentina. BNZ is the N-benzyl-2-nitro-1-imidazoleacetamide molecule. Different mechanisms of action have been attributed to BNZ. For example, it is suggested that it may act by a reductive stress, involving covalent modifications in DNA, proteins and lipids (Sales Junior et al., 2017) . Also, BNZ could be reduced by a type I nitroreductase (NTR) present in the parasite, followed by several reactions that cause the release of dialdehyde glyoxal that has trypanocide effect by forming adducts with guanosine bases in DNA and RNA (Kratz et al., 2018) . Furthermore, BNZ may increase the phagocytosis and lysis of the parasite and inhibit its growth by the action of the enzyme fumarate reductase-NADH Sobrinho et al., 2007) .
Low benefit in the chronic phase of the disease, regional variations in efficacy and emergence of resistant strains are some limitations of the clinical use of BNZ (Sobrinho et al., 2009 ). In addition, it causes a number of side effects such as rash, epigastric pain pruritus, nausea, abdominal swelling and some severe manifestations as eosinophilia (Oliveira et al., 2017) . Recently, the multicenter clinical trial "Benznidazole Evaluation for Interrupting Trypanosomiasis" (BENEFIT) demonstrated that the use of BNZ did not lead to clinical improvements in patients with established Chagas' cardiomyopathy when compared to the placebo group, even those with New York Heart Association (NYHA) class I or II heart failure, despite a reduction in parasite load (Morillo et al., 2015) .
Repositioning of therapeutic drugs
Repositioning of established pharmacotherapeutic agents with wellknown activity and side effect profiles is considered an effective strategy for the development of new treatments for several diseases, especially for neglected disorders. This repositioning approach is advantageous in view of the cost and time-consuming process required compared to the development of new medicines, since the drugs used in repositioning already have their toxicological and pharmacokinetic profile assessed when used on their previous therapeutic target (Alberca et al., 2016) .
Several compounds of different pharmacological classes have already been tested against the T. cruzi (Table 1) . Among them, benidipine, a calcium channel blocker usually administered for the treatment of hypertension and angina, and the antibiotic clofazimine were tentatively used against the parasite since they act inhibiting cruzipain, the main lysosomal cysteine protease with an important role in parasite infectivity. The inhibition of cruzipain has been much explored, because it is the most abundant protease of the parasite. Cruzipain has been shown to be crucial for all stage of the parasite life cycle and is involved in the parasite nutrition, invasion of mammalian cells and evasion of the host immune response Rogers et al., 2012; Salas-Sarduy et al., 2017) . Thus, benidipine and clofazimine were considered promising candidates for the treatment of the disease in view of their capacity to reduce the parasitic burden in the blood and skeletal tissues of infected mice, additionally curtailing the inflammatory effects of the infection. The use of these drugs in combination with current adopted therapy should be further evaluated .
Other repositioning drugs potentially useful in the ancillary treatment of Chagas disease were clomipramine, sertraline and fexinidazole. Clomipramine, a tricyclic antidepressant, was able to increase the survival of infected mice, reducing parasitemia, although it was not capable of eliminate the T. cruzi. Its beneficial action was initially associated to the inhibition of trypanothione reductase (TR), a unique enzyme that interacts with Flavin-adenine dinucleotide (FAD) and reduces nicotinamide adenine dinucleotide phosphate (NADPH), which is essential to parasite survival (Fauro et al., 2013; Benson et al., 1992) . However, this hypothesis diverges from studies showing that the trypanocide effect would only be achieved by almost total inhibition of the TR, what is not obtained with this drug (Krieger et al., 2002; Mendonça et al., 2018) . Sertraline is also indicated for the treatment of depression and anxiety, and its use in CD in vitro experiments showed efficacy against intracellular and bloodstream forms, with low cytotoxicity to V. Ribeiro, et al. IJP: Drugs and Drug Resistance 12 (2020) 7-17 mammalian cells (Ferreira et al., 2018) . Fexinidazole is a promising broad spectrum antiparasitic agent with clinical trials already taking place. This compound has a nitro group in its composition that is metabolized by the parasite nitroreductases, forming reactive species that inhibits DNA synthesis (Bahia et al., 2012 (Bahia et al., , 2014 . Mice treated with fexinidazole at both phases of the infection, and accompanied by bioluminescence, showed a higher cure rate when compared to the groups treated with reference drugs, even after promoting immunosuppression after treatment (Francisco et al., 2016) . Mice treated with fexinidazole at both phases of the infection, and accompanied by bioluminescence, showed a higher cure rate when compared to the groups treated with reference drugs, even after promoting immunosuppression after treatment (Francisco et al., 2016) . Of interest, fexinidazole has been approved by the European Medianes Agency (EMA) for the treatment of African Trypanosomiasis, in both adults and children (Deeks, 2019) , thus demonstrating its therapeutic potential to be applied to CD. Probably, dose and treatment time adjustments may be required for clinical trials (Watson et al., 2019) .
Dietary supplements have also been evaluated in CD treatment. Resveratrol, considered a food supplement by health surveillance agencies, has antioxidant and cardioprotective properties, acting in the chronic phase of the disease by non-trypanocidal mechanisms (Vilar-Pereira et al., 2016) . Furthermore, resveratrol acts as a neuroprotector during CD, improving gliogenesis and neural migration (Fracasso et al., Table 1 Repositioning of therapeutic drugs for Chagas disease treatment.
References
Repositioning of therapeutic drug/original indication Culture type/animal type Main Results
Buckner et al., 2012
Derivatives of Tipifarnib (anti-cancer drug) Swiss mice Highly potent against the parasite, but with lesser cure than posaconazole. Bahia et al. (2012) Fexinidazole (a broad-spectrum antiprotozoal drug)
Swiss mice
Early treatment can reduce heart inflammation associated with the chronic CD. It is well tolerated by the animals, without the occurrence of adverse effects. Apt et al. (2013) Itraconazole (triazole antifungal agent) Patients (human) Possibility of itraconazole to cure the heart disease associated with T. cruzi, which may interrupt or delay the natural evolution of the disease. There were few adverse effects. Fauro et al. (2013) Clomipramine: tricyclic antidepressant Albino Swiss mice It reduced the parasite load, without eliminating the presence of the parasite in the host. There was a relevant reduction of lesions caused by the disease, such as fibrosis. Bahia et al. (2014) Fexinidazole metabolites (antiparasitic) Murine macrophages, Swiss mice
The metabolites were effective in treating the disease superior to Fexinidazole and benznidazole, without inducing toxicity in the experimental models. Molina et al. (2014) Posaconazole (triazole antifungal) Patients (human) Posaconazole treatment was not effective, with high percentages of therapeutic failures. Da Silva et al., 2015 Auranofin (Antirheumatic) Human fibroblast, Balb/c mice The drug has trypanocidal activity higher than benznidazole, increasing the survival of treated animals without reducing parasitemia. However, the drug has reduced selectivity, presenting toxicity. Sbaraglini et al. (2016) Benidipine (Anti-Bacterial Agents) and clofazimine (Calcium Channel Blocker) C3H/HeN mice Reduced the parasite load and the resulting infection.
Vilar-Pereira et al.,.
Resveratrol (antioxidant/cardioprotective) Balb/c mice The compound is able to improve the cardiac integrity of infected animals, provide risk factors for cardiovascular mortality, restore ejection fraction, and edit the parasitic burden on the heart. Carvedilol (Adrenergic Blocker) C57BL/6 mice For this experimental model, carvedilol therapy was not able to alter levels of circulating parasites, but modulates the pattern of mediators of CCL2 and IL-10 when the VL10 strain of T. cruzi.
Reigada et al., 2017
Isotretinoin (Antiacne) CHO-K1 cells Isotretinoin inhibited polyamine transport, also showed strong inhibition of the explanted trypomastigote of infected cells but being significantly less effective at the epimastigote stage. Hernández et al. (2018) Curcumin (cholagogue, anti-inflammatory) Human microvascular endothelial cells, C57BL/6 mice Reduced inflammatory cell infiltration without lowering parasitemia.
Ferreira et al. (2018) Sertraline (Antidepressant)
In silico studies, Balb/c mice Efficacy against intracellular amastigotes and bloodstream trypomastigotes, with low cytotoxicity to mammalian cells Fracasso et al., 2018 Resveratrol (antioxidant/cardioprotective) Swiss mice Can be use for the treatment of neuroinflammation or neuroprotection during Chagas disease, improving gliogenesis and restoring neural migration. Simões-Silva et al.
Imatinib (Antineoplastic Agent Immunological Agent)
Mouse fibroblasts
The drug was moderately active against the parasite, with low selectivity index ND* not determined.
V. Ribeiro, et al. IJP: Drugs and Drug Resistance 12 (2020) 7-17 2019). Curcumin, a herbal supplement and a natural food coloring extracted from ginger, is a natural phenol that failed in reducing parasitemia, although lowering inflammatory leukocyte infiltration (Hernández et al., 2018) . Like curcumin, several repositioning attempts failed to achieve the expected results. For example, auronofin, a compound derived from gold, generally prescribed for the treatment of rheumatoid arthritis, showed ability to increase the survival of mice infected with the parasite without reducing parasitemia and with reduced selectivity (Da Silva et al., 2016) . Nitazoxanide, a broad-spectrum antiparasitic drug that inhibits the parasitic intracellular enzyme pyruvate-ferredoxin oxidoreductase (PFOR) and blocks the ion channel of glutamate chloride, disclosed poor results against the T. cruzi worsening the infection in mice, increasing tissue damage in relation to untreated animals, and exhibiting an increased mortality. Consequently, this compound was considered highly unsafe (Valle-Reyes et al., 2017) .
Other drugs comprised in the strategy of therapeutic repositioning belong to the class of sterol biosynthesis inhibitors that are components of the parasitic membranes and essential for the cellular growth . A 20-year follow-up study of patients treated during 120 days with itraconazole, a synthetic analogue derived from imidazole, showed the drug capacity to interrupt or delay the natural course of CD during the chronic phase, causing regression of some abnormalities on the electrocardiogram and showing few adverse effects (Apt et al., 2013) . However, in this research, problems in the control group and poor sensitivity of the used tests to determine cure were observed; so further studies are needed to confirm the findings.
The prospective, randomized clinical trial of CHAGASAZOL evaluated the efficacy and safety of posaconazole, an antifungal that actively inhibits the synthesis of ergosterol, the main sterol of the parasite. Contrary to previous findings in vitro and in experimental models of Chagas disease, which posaconazole showed excellent activity, the drug failed to disclose the same expected efficacy in humans (Molina et al., 2014) . The results in the human trial were recapitulated in a study using bioluminescent parasites in a mouse model, which confirmed the low efficacy of posaconazole in both acute and chronic phases of the disease (Francisco et al., 2015) . The use of ravuconazole was evaluated in a phase 2 clinical trial in patients in undetermined chronic phase, without cardiac damage. Of interest, it was observed that the prodrug E1224 led to parasite clearance, but with transient response when using low-or short doses regimens (Torrico et al., 2018) .
Drug association
The concomitant or sequential use of two or more pharmaceutical compounds represents an alternative that is also being explored in CD treatment studies (Table 2) . Theoretically, the combination of different compounds allows the reduction of the doses and/or treatment length, resulting in reduction of drug adverse side effects and costs. Synergistic treatment generally improves compounds activity with distinct mechanisms of action, and additionally reduces the drug toxicity and the chance of developing resistance (Ferreira and Andricopulo, 2016; Andrews et al., 2014) .
A successful association between itraconazole and BNZ was demonstrated in a murine model. The concomitant administration of both drugs allowed a decrease in BNZ dose by 25% and on time needed to curtail the parasitemia. In addition, mice treated with this drug combination showed lessened lesions in the cardiac tissue and fewer inflammatory cells associated with the chronic phase of the disease (Martins et al., 2015) . Itraconazole seems to alter the pharmacokinetic profile of BNZ, increasing its half-life and its volume distribution extent, allowing an increased accumulation of BNZ in the biological systems (Da Silva et al., 2012; Martins et al., 2015) . Diniz et al. (2013) , using a seven-day rapid treatment protocol, observed that the combination of BNZ and posaconazole was more effective compared to using each one alone. Additionally, the association allowed reduced doses compared to individual administration.
The combination of BNZ and clomipramine showed a synergic activity against T. cruzi (Strauss et al., 2018) , and attenuated necrosis and liver damage, possibly due to the hepato-protective effect of the antidepressant. Effectively, mice treated with the association of these drugs disclosed less renal damage when compared to the group treated with BNZ alone (Strauss et al., 2013) . Besides that, they showed reduced parasitemia and mortality rate (Strauss et al., 2018) .
In a murine model of chronic Chagas cardiomyopathy the concomitant use of simvastatin, a lipid-lowering medication, and BNZ decreased fibrosis and inflammation. Importantly, both drugs are wellstudied, with a well-established safety profile, requiring no further expensive and long-term clinical studies (González-Herrera et al., 2017) . Furthermore, the sequential use of BNZ and allopurinol (used in the treatment of gout) was well tolerated in humans, leading to beneficial therapeutic immunological changes during the chronic CD, significant reduction of parasitic loads, absence of electrical abnormalities in the heart, and increased cure rate (Perez-Mazliah et al., 2012; Rial et al., 2018; Mazzeti et al., 2019) . Other combinations with BNZ that have shown to be interesting and deserve better investigation are ascorbic acid (Providello et al., 2018) , hydroxymethylnitrofurazone (Scarim et al., 2018a,b) , and imidazole .
New drugs
Despite the high cost and the time required to search new compounds, this is the main strategy to identify novel treatments for CD in recent years (Table 3 . These new drugs, of natural or synthetic origin, are being tested but they still in the pre-clinical phase. Most of them show activity against the parasite, however, in many cases, their mechanisms of action have not yet been elucidated. For example, studies with Cordycepin/Pentostatin and with the Piper jericoense plant showed that these compounds have trypanocide effects, but it is not completely known in which pathways of the parasite they are acting (do Carmo et al., 2019; García-Huertaz et al., 2018) .
Psilostachin (Psi) and Psilostachin C (PsiC) (sesquiterpene lactones) are natural compounds found in the Asteracea family that have displayed activity against the parasite by different mechanisms of action. Psi possibly interacts with the heme group, and PsiC inhibits the synthesis of ergosterol. Both compounds showed interaction with hemin, a product of hemoglobin digestion essential for parasite survival (Sülsen et al., 2016) . Of interest, the sesquiterpene lactone isolated from Lychnophora trichocarpha loaded with nanoparticles was able to reduce parasitemia and increases the lifetime of treated animals (Branquinho et al., 2014) .
Natural chemical constituents isolated from the cashew nut Anacardium occidentale showed trypanocide effects similar to those of benznidazole, by inhibition of T. cruzi sirtuins (Bastos et al., 2019) . Furofuran lignan and Eupomatenoid-5, isolated from the leaves of Piper jericoense and Piper regnellii respectively, acted against the three evolutionary forms of the parasite (García-Huertaz et al., 2018; Lazarin-Bidóia et al., 2013) . The last decreases the activity of the enzyme trypanothione reductase, resulting in increased amount of oxygen and nitrogen reactive species and the death of T. cruzi. Interestingly, thiazolidine LPSF SF29, a synthetic compound, interferes with the biosynthesis of the substrate of the enzyme trypanothione reductase, also causing mitochondrial dysfunction and parasite death (De B. Moreira et al., 2013) .
Several molecules with probable mechanism of action on the parasite sterol biosynthesis were also tested. The enzyme sterol 14-Demethylase (CYP51) is essential for the synthesis of sterols, and its inhibition is used as a pharmacological target. Azole sterol biosynthesis inhibitors, such as, VNI (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazole-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadi-azol-2-yl)benzamide, inhibitor of protozoan CYP51, and VNF, (R)-4-chloro-N- (1-(2,4- 
increased the Benznidazole (Antiprotozoal) and Posaconazole (Antifungal) Swiss mice They presented synergism when administered together, being able to reduce the parasitemia to values inferior to those obtained with administration of the drugs alone. Strauss et al. (2013) Clomipramine (Antidepressant,Tricyclic) and Benznidazole (Antiprotozoal)
Swiss mice
Prevented cardiac conduction abnormalities in animals. In addition, the association prevented the formation of perivascular necrosis and inflammation in the liver Martins et al. (2015) Benznidazole ( 
Ascorbic Acid (Genitourinary Agent) Benznidazole (Antiprotozoal)
Reduction in parasitemia, in cardiac parasitism and inflammation, and prevention of the hepatic damage. Scarim et al. (2018) Hydroxymethylnitrofurazone (a nitrofurazone prodrug) Benznidazole (Antiprotozoal) Balb/c mice Amastigote nests were not found in heart, skeletal muscle, liver, kidney, colon, spleen and brain. The histopathological analysis showed fewer tissue lesions and parasite infiltrates Torrico F et al. 
RAW264.7 macrophages
The analogs were reduced in toxicity as a mutagenesis of the analogs was detected at a concentration greater than the lower concentration of megazole. Papadopoulo et al.,. 2013 Novel 3-nitro-1H-1,2,4-triazole (Based compounds)
Caco-2 cells, L6 cells and Balb/c mice
Among the compounds tested, some showed the ability to reduce parasitemia, two compounds did not present in vivo activity. Jiménez-Coello et al., 2013 Carica papaya (Seed extract) Balb/c mice The compound shows activity only against the trypomastigote form with antioxidant activity. Raviolo et al., 2013 C6-alkyl (2a-c) and N1-acyl (3a-c) (derivatives of Allopurinol, Allop)
Mammalian cells (murine splenocytes) and Vero cells
Only 1 of the compounds, called 3c, has activity against the parasite, with better solubility and lipophilicity than allopurinol, in addition to a reduction in cytotoxicity Hargrove et al. (2013) UDO e UDD (pyridine derivative) L6 cells and Swiss mice The compounds are effective against T. cruzi, being selective against the parasite. The heme-heterocycle and apoprotein-ligand interactions may be helpful in minimizing the off-target activity of CYP51 inhibitors and directing the design selective drugs. Fonseca-Berzal et al., 2013 Tetrahydroquinolines (Organic compound, derivative of quinoline)
Murine fibroblasts and Vero cells
The showing less effectiveness than the reference drug but also accomplishing great selectivity on the intracellular stage. Low toxicity, however the compounds present solubility problems. Adade et al., 2013 Melittin ( (continued on next page) V. Ribeiro, et al. IJP: Drugs and Drug Resistance 12 (2020) 7-17 Vero cells and Balb/c mice Four showed greater in vitro activity than benznidazole, reducing the number of amastigotes in infected cells. In vivo, the compound succeeded in eradicating the parasites in most animals. Papadopoulo et al.
Nitrotriazole-based derivative L6 cells and Balb/c mice The 3-nitrotriazole compounds showed potent and selective anti-T. cruzi activity. Cortes et al., 2015 Four gallic acid derivatives Vero cells The compounds showed high selectivity, and two were more potent against the parasite superior to nifurtimox. Porcelia macrocara (acetylene fatty acid derivatives)
NCTC cells
The derivative 1 exhibited activity against trypomastigotes of T. cruzi ten times more effective than the benznidazole. Palace-Berl et al., 2015 5-substituted hydrazides (compounds derived)
LL-24 human fibroblast cells All of the derivatives, except for one, showed increased trypanocidal activity against the three strains compared to BZD. 62% of the compounds were more active than nifurtimox against the Y strain. Mendoza-Martínez et al., 2015 Quinazoline derivatives Vero cells and CD1 mice 4 of the 9 compounds (44%) presented higher activity than the reference drugs. Wong-Baeza et al., 2015 Benzyl ester of N-propyl oxamate Vero cell line and NIH albino mice
The polar NPOx showed no trypanocidal activity. In contrast, the hydrophobic B-NPOx ester exhibited trypanocidal activity in vitro and in vivo. Álvarez et al., 2015 Amide-containing thiazole Vero cells and CD-1 mice Thiazole 4 was active against trypomastigotes and prevented the intracellular growth of amastigotes. Thiazole 4 suppressed parasitemia by modifying the anti-antibodies as the reference drug. Olmo et al., 2015 Abietic acid derivatives (diterpenoid) Vero cells and Balb/c mice Tests in the acute phase inhibited parasitemia more than Bz, and decrease in reactivation of parasitemia was found in the chronic phase after immunosuppression. Neitz et al., 2015 GNF7198 (xanthine analogue) C2C12 cells, 3T3 cells, C2C12 cells, CACO 2 cells and Balb/c mice The xanthine analogs showed in vitro activity against the parasite and were able to reduce parasitemia more than benznidazole in the animal model. Khare et al. (2016) GNF 6702 (selective inhibitor of the kinetoplastid proteasome)
NIH 3T3 fibroblast cells and Balb/c mice
The compound shows activity in the parasitemia reduction, confirmed after immunosuppression of the animals. Sülsen et al. (2016) Psilostachyin and Psilostachyin C (Sesquiterpene Lactones)
Action of 2 compounds on T. cruzi
The compounds possess activity against the parasite by different mechanisms of action. The association these compound may be further investigated as a new therapeutic modality for the treatment. Arias et al., 2016 Nitrofuran derivatives HeLa cells and mammalian cells The three compounds were shown to be better inhibitors of trypanothione reductase than Nifurtimox. (continued on next page) V. Ribeiro, et al. IJP: Drugs and Drug Resistance 12 (2020) 7-17 survival of T. cruzi-infected animals. These compounds have low toxicity, absence of mutagenicity and high selectivity index. In the parasite, such compounds cause damage by inducing morphological changes, leading to the formation of vesicles on the membranes, swelling and mitochondrial disorganization. NIV has additionally other important advantages, such as low cost, satisfactory oral bioavailability, disclosing beneficial effect in experimental CD both during the acute and chronic phase. Pyridine-based compounds, identified as pyridine derivatives (S)-(4-chlorophenyl)-1-(4-(4-(trifluoromethyl)phenyl)-piperazin-1-yl)-2-(pyridin-3-yl)ethanone (UDO) and N-[4-(trifluoromethyl)phenyl]-N-[1-[5-(trifluoromethyl)-2-pyridyl]-4-piperidyl]pyridin-3-amine (UDD), are inhibitors of the non-azolic CYP51 enzyme, exhibiting efficiency against T. cruzi similarly to that obtained with posaconazole. Contrastingly, they display an excellent selectivity (Hargrove et al., 2013; Soeiro et al., 2013; Villalta et al., 2013) . Amides and carbinols based on 3-nitrotriazole were developed as bifunctional compounds against T. cruzi. They act by inhibiting the enzyme CYP51 and are also substrates for the nitroreductase type I (NTR) enzyme, thus combining the effects of nitroheterocyclics and inhibitors of ergosterol synthesis against the parasite. They are capable of eliminate the parasite completely within 10 days of treatment in the acute murine model. Moreover, unlike the 2-nitrotriazole derivatives, these compounds have no mutagenic potential (Papadopoulou et al., 2015) . Branquinho et al., 2017 Lychnopholide (lipophilic sesquiterpene lactone) ND* The best performance was obtained with PLA-PEG NC, PCL NC also showed promising results. In addition to improving LYC pharmacokinetic parameters (iv), the NC protected the encapsulated LYC from degradation in mouse plasma. García-Huertaz et al. ND* not determined.
Still regarding synthetic drugs under investigation, the compound GNF6702, proposed by Khare et al. (2016) , showed significant activity against T. cruzi by inhibiting the proteasome chymotrypsin-like activity, without any action on human proteasome. Currently, this compound is undergoing pre-clinical toxicological tests.
Conclusion
Although CD was discovered more than 100 years ago, the treatment remains inefficient for patients already in the heart phase of the disease. Several strategies have been followed to improve therapeutic treatment against CD: the use of the approved drugs BNZ and NF, the repositioning drugs from other pharmacological classes, the association of different compounds and through the search for more effective new drugs.
From this review, it is possible to conclude that: (a) despite the limited activity of BNZ in the chronic CD, nowadays this is the only treatment available in developing countries, such as Brazil. Thus, is imperative to develop new alternatives drugs in view of the detrimental effects of the infection during the symptomatic chronic phase; (b) the use of BNZ in combination with other compounds has shown advantages compared to its use alone; (c) the search for new pharmacological alternatives has been the most used strategy to find new effective drugs; (d) most of the current studies are either at the stage of animal experimentation or in preclinical phases; (e) the inhibition of the parasite ergosterol biosynthesis has been widely explored as a pharmacological target, especially with the use of antifungal drugs, although poor clinical results.
Brief perspective
An innovative line of research, which seeks to use unconventional strategies can be currently observed. For example, the study by Villanueva-Lizama et al. (2018) suggests the possibility of employing vaccines as a potential pharmacological treatment. Using the antigens trypomastigote surface antigen-1 (TSA-1) and flagellar calcium binding protein of 24 kDa (Tc24), researchers showed that corresponding recombinant proteins have the ability to stimulate the immune system, establishing an immune response against these antigens during the infection natural course. In turn, Konduri et al. (2017) produced a vaccine based on dendritic cells, transduced with the dnSHP adenoviral construct and loaded with the Tc24 recombinant protein to reduce or prevent cardiac complications of CD.
In addition, many studies utilize computational approaches to identify potential inhibitors of T. cruzi crucial molecular targets (Scarim et al., 2018a,b) . Melo-Filho et al., 2019 used a virtual screening based on quantitative structure-activity relationships (QSAR) model to prospect novel molecules against the T. cruzi in commercial database. This model made possible the identification of seven potent and selective compounds against the parasite, which were validated in in vitro experiments. In another study, the virtual screening approach was used on a protein-based pharmacophore to detect potential targets of the glycolytic pathway of the parasite, enabling the identification of three distinct inhibitors of the glyceraldehyde-3-phosphate dehydrogenase from T. cruzi (Maluf et al., 2013) .
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